An Australian guideline for rheumatic fever and rheumatic heart disease: An abridged outline

Medical Journal of Australia

Volumn 186, Issue 11, 2007, Pages 581-586

  Carapetis, Jonathan R ^a   Brown, Alex ^b   Wilson, Nigel J ^c   Edwards, Keith N ^d   Walsh, Warren ^e   Hadfield, Clive ^e   Lennon, Diana ^e   Purton, Lynette ^e   Wheaton, Gavin ^e  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^d NORTHERN TERRITORY DEPARTMENT OF HEALTH   (Australia)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BENZATHINE PENICILLIN; CARBAMAZEPINE; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; GLUCOCORTICOID; INFLUENZA VACCINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PENICILLIN V; PNEUMOCOCCUS VACCINE; SALICYLIC ACID DERIVATIVE; VALPROIC ACID;

ARTHRALGIA; ARTHRITIS; ARTICLE; AUSTRALIA; BACTERIAL ENDOCARDITIS; CARDITIS; CHOREA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG SAFETY; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROGRAM; HEART VALVE SURGERY; HIGH RISK POPULATION; HUMAN; INJECTION SITE BLEEDING; LABORATORY TEST; MATERNAL TREATMENT; MEDICAL RECORD; MONARTHRITIS; MORBIDITY; PATIENT CARE PLANNING; PATIENT COMPLIANCE; POVERTY; PRACTICE GUIDELINE; RECURRENT DISEASE; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SECONDARY PREVENTION; SINGLE DRUG DOSE; STREPTOCOCCUS INFECTION; VALVULAR HEART DISEASE;

EID: 34250677280     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb01059.x     Document Type: Article

References (19)

1. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia: an evidence-based review. Melbourne: NHFA, 2006. http://www.heartfoundation.com.au/ downloads/ARF_RHD_PP-590_Diag-Mgnt_Evidence-Review_0606.pdf (accessed May 2007).
2. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, 1999.
3. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998; 68: 899-917. http://www.nhlbi.nih.gov/guidelines/ obesity/ob_home.htm (accessed May 2007).
4. WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease. Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation, Geneva, 29 Oct - 1 Nov 2001. Geneva: WHO, 2004. (WHO Technical Report Series No. 923.)
5. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-694.
6. Australian Institute of Health and Welfare. Rheumatic heart disease: all but forgotten in Australia except among Aboriginal and Torres Strait Islander peoples. Bulletin No. 16. Canberra: AIHW, 2004. (AIHW Cat. No. AUS 48.)
7. Hanna JN, Heazlewood RJ. The epidemiology of acute rheumatic fever in Indigenous people in north Queensland. Aust N Z J Public Health 2005; 29: 313-317.
8. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord 2005; 5: 11.
9. Carapetis JR. A review of the technical basis for the control of conditions associated with group A streptococcal infections. Geneva: World Health Organization, 2004. (WHO/FCH/CAH/05.08.) http://www.who.int/ childadolescent-health/New_Publications/CHILD_HEALTH/DP/ WHO_FCH_CAH_05.08.pdf (accessed May 2007).
10. Guidelines for the diagnosis of rheumatic fever. Jones criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever Endocarditis and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992; 268: 2069-2073.
11. Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2003; (2): CD003176.
12. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 2002; (3): CD002227.
13. Spinetto HD. The Auckland Rheumatic Fever Register 1993-1999: an audit [Masters thesis]. Auckland: Auckland University, 2002.
14. Lue HC, Wu MH, Hsieh KH, et al. Rheumatic fever recurrences; controlled study of 3-week versus 4-week benzathine penicillin prevention programs. J Pediatr 1986; 108: 299-304.
15. Padmavati S, Gupta V, Prakash K, Sharma KB. Penicillin for rheumatic fever prophylaxis 3-weekly or 4-weekly schedule? J Assoc Physicians India 1987; 35: 753-755.
16. Lue HC, Wu MH, Wang JK, et al. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr 1994; 125: 812-816.
17. Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. Med J Aust 2006; 184: 514-517.
18. Carapetis JR, Powers JR, Currie BJ, et al. Outcomes of cardiac valve replacement for rheumatic heart disease in Aboriginal Australians. Asia Pacific Heart J 2000; 8: 138-147.
19. McDonald M, Brown A, Noonan S, Carapetis JR. Preventing recurrent rheumatic fever: the role of register based programmes. Heart 2005; 91: 1131-1133.